Richard Goldberg/cancerletter.com
May 4, 2025, 12:58
Agenus supports Richard Goldberg’s call for evolving drug development models
Agenus shared a post on X by The Cancer Letter, adding:
“As Dr. Goldberg eloquently states, the time is now to evolve how we develop and assess innovative treatments.
At Agenus, our mission is rooted in bringing potential life-changing therapies—like BOT/BAL—to patients who have long been underserved.”
Quoting The Cancer Letter‘s post:
“Richard M. Goldberg:
My hope for Makary’s new role is that he will embrace new models in drug development to make sure that we are properly evaluating the benefits of the new tools we have in our toolbox.”
Read more about Dr. Goldberg’s perspective on innovative drug development.
Learn more about drug development on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 8, 2025, 20:27
Jul 8, 2025, 18:55
Jul 8, 2025, 18:00